Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain

Brain Research

Volumn 797, Issue 2, 1998, Pages 225-233

  Patel, Nilesh A ^a,b   Moldow, Roberta L ^a   Patel, Jitesh A ^a   Wu, Gao De ^a,c   Chang, Sulie L ^a  

^a Seton Hall Univ 400 S Orange Ave ^*  (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c Chinese Academy   (China)

Author keywords

Arachidonylethanolamide; Cannabinoid receptor; FOS; Immunocytochemistry; Marijuana

Indexed keywords

ANANDAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG RECEPTOR BINDING; GENE ACTIVATION; GENETIC REGULATION; IMMEDIATE EARLY GENE; IMMUNOREACTIVITY; LIGAND BINDING; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTO ONCOGENE; RAT; THALAMUS MIDLINE NUCLEUS;

ANIMALS; ARACHIDONIC ACIDS; BRAIN CHEMISTRY; CALCIUM CHANNEL BLOCKERS; CANNABINOIDS; DIENCEPHALON; EPENDYMA; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; POLYUNSATURATED ALKAMIDES; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TELENCEPHALON; TIME FACTORS;

EID: 0032577996     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00364-3     Document Type: Article

References (40)

1. Abood M., Martin B. Molecular neurobiology of the cannabinoid receptor. Int. Rev. Neurobiol. 39:1996;197-221.
2. Aronin N., Sagar S.M., Sharp F.R., Schwartz W. Light regulates expression of a FOS-related protein in the rat SCN. Proc. Natl. Acad. Sci. USA. 87:1990;5959-5962.
3. Behbehani M.M. Functional characteristics of the midbrain periaqueductal gray. Prog. Neurobiol. 46:1995;575-605.
4. Bot G., Chahl L.A. Induction of fos-like immunoreactivity by opioids in guinea-pig brain. Brain Res. 731:1996;45-46.
5. Chahl L.A., Leah J., Herdegen T., Trueman L., Lynch-Frame A.M. Distribution of c-fos in guinea-pig brain following morphine withdrawal. Brain Res. 717:1996;127-134.
6. Chang S.L., Squinto S.P., Harlan R.E. Morphine activation of c-fos expression in the rat brain. Biochem. Biophys. Res. Commun. 157:1988;698-704.
7. Chang S.L., Ren T., Zadina J.E. Interleukin-1 activation of FOS proto-oncogene protein in the rat hypothalamus. Brain Res. 617:1993;123-130.
8. Chang S.L., Patel N.A., Romero A.A. Activation and desensitization of Fos immunoreactivity in the rat brain following ethanol administration. Brain Res. 679:1995;89-98.
9. Chang S.L., Patel N.A., Romero A.A., Thompson J., Zadina J.E. FOS expression induced by interleukin-1 or acute morphine treatment in the rat hypothalamus is attenuated by chronic exposure to morphine. Brain Res. 736:1996;227-236.
10. Clark M., Weiss S.R.B., Post R.M. Expression of c-fos mRNA in rat brain after intracerebroventricular administration of corticotropin-releasing hormone. Neurosci. Lett. 132:1991;235-238.
11. Coolen L.M., Peters H.J.P.W., Veening J.G. Fos immunoreactivity in the rat brain following consummatory elements of sexual behavior: sex comparison. Brain Res. 738:1996;67-82.
12. Crawley J.N., Corwin R.C., Robinson J.K., Felder C.C., Devane W.A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46:1993;967-972.
13. J.S. De Olmos, The amygdaloid projection field in the rat as studied with the cupric-silver method, in: B.E. Eleftheriou (Ed.), The Neurobiology of Amygdala, Plenum, New York, 1978, pp. 145-204.
14. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that bonds to the cannabinoid receptors. Science. 258:1992;1946-1949.
15. Felder C.C., Nielsen A., Briley E.M., Palkovits M., Priller J., Axelrod J., Nguyen S.N., Richardson J.M., Riggin R.M., Koppel G.A., Paul S.M., Becker G.W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
16. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayan P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
17. 2). Peptides. 15:1994;1505-1511.
18. Gorski R.A., Gordon J.H., Shryne J.E., Southam A.M. Evidence of a morphological sex difference within the median preoptic area of the rat brain. Brain Res. 148:1978;333-346.
19. Hoffman G.E., Lew W., Abbud R., Lee W.S., Smith M.S. Use of FOS-related antigens (FRAs) as markers of basal activity: FRA changes in dopamine neurons during proestrus, pregnancy and lactation. Brain Res. 654:1994;207-215.
20. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L., De Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. 87:1990;1932-1936.
21. Imaki T., Shibasaki T., Hotta M., Demura H. Intracerebroventricular administration of corticotropin-releasing factor induces c-fos mRNA expression in rat brain regions related to stress responses: comparison with pattern of c-fos mRNA induction after stress. Brain Res. 616:1993;114-125.
22. Jacobson L., Sapolsky R. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocrine Rev. 12:1991;118-134.
23. T.R. Kosten, L.E. Hollister, in: B.G. Katzung (Ed.), Drugs of Abuse, 7th edn., Appleton and Lange, Stamford, 1998, pp. 516-532.
24. Lichtman A.M., Dimen K.R., Martin B.R. Systemic or intrahippocampal cannabinoids administration impairs spatial memory in rats. Psychopharmacology. 119:1995;282-290.
25. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence of supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 267:1996;585-593.
26. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268:1994;1612-1623.
27. Matsuda L.A., Bonner T.I., Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327:1993;535-550.
28. Miyamoto A., Yamamoto T., Ohno M., Watanabe S., Tanaka H., Morimoto S., Shoyama Y. Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of FOS protein in rat brain. Brain Res. 710:1996;234-240.
29. Morgan J.I., Cohen D.R., Hemstead J.L., Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. Science. 237:1987;192-197.
30. Morgan J.I., Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu. Rev. Neurosci. 14:1991;421-451.
31. Nozaki K., Boccalini P., Moskowitz A. Expression of c-fos like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience. 49:1992;669-680.
32. Rizvi T.A., Murphy A.Z., Ennis M., Behbehani M.M., Shipley M.T. Median preoptic area afferents to periaqueductal gray medullo-output neurons: a combined fos and tract tracing study. J. Neurosci. 16:1996;333-344.
33. Romero J., Garcia L., Cabeira M., Zadrozny D., Fernandez-Ruiz J.J., Ramos J.A. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci. 56:1995;2033-2040.
34. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoum R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
35. Souilhac J., Poncelet M., Rindaldi-Carma M., Le Fur G., Soubrie P. Intrastriatal injection of cannabinoid receptor agonists induced turning in mice. Pharmacol. Biochem. Behav. 51:1995;3-7.
36. Terranova J.P., Storme J.J., Lafon N., Perio A., Rinaldi-Carmona M., Le Fur G., Soubrie P. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR141716. Psychopharmacology. 126:1996;165-172.
37. C. Van Hartesveldt, The hippocampus and regulation of the hypothalamic-hypophyseal-adrenal cortical axis, in: R.L. Isaacson, K.H. Pribram (Eds.), The Hippocampus, Vol. 2, Plenum, New York, 1976, pp. 375-391.
38. O.S. Vinogradova, Functional organization of the limbic system in the process of registration of information: facts and hypothesis, in: R.L. Isaacson, K.H. Pibram (Eds), The Hippocampus, Vol. 1, Plenum, New York, 1975, pp. 3-69.
39. Wegner T., Jamali K.A., Juaneda C., Leonardelli J., Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem. Biophys. Res. Commun. 237:1997;724-728.
40. Weidenfeld J., Feldman S., Mechoulam M. Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology. 59:1994;110-112.